Analytical Data
-
Gene name
CDK6-CCND2 Heterodimer
- Application
-
Alternative Names
PLSTIRE; Cell division protein kinase 6; Serine/threonine-protein kinase PLSTIRE
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q00534
-
Expression Region
Met1~Ala326
-
Molecular Weight
41kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The CDK6-CCND2 heterodimer has garnered significant attention in cancer research due to its critical role in regulating cell cycle progression. Cyclin-dependent kinase 6 (CDK6) is a serine/threonine kinase that, when paired with cyclin D2 (CCND2), facilitates the transition from the G1 phase to the S phase of the cell cycle. This transition is crucial for cellular proliferation, and aberrations in this mechanism can lead to uncontrolled cell division, a hallmark of cancer. Various studies have shown that dysregulation of CDK6 and CCND2 is associated with several malignancies, including leukemia and solid tumors. As a result, targeting this heterodimer presents a promising strategy for developing novel cancer therapies. Researchers are increasingly focusing on characterizing the structural and functional properties of the CDK6-CCND2 complex to understand its interactions with other cell cycle regulators and signaling pathways. Moreover, the production of recombinant CDK6-CCND2 proteins allows for in-depth biochemical assays, facilitating the identification of small-molecule inhibitors that could effectively disrupt its function. This research aims to elucidate the specific roles of CDK6 and CCND2 in tumorigenesis, ultimately contributing to the development of targeted therapeutic interventions that may improve clinical outcomes in cancer patients.
